

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Integrin $\alpha_v\beta_3$	<p>A study in mice suggests that inhibiting integrin $\alpha_v\beta_3$ could be useful for preventing cancer metastasis to the brain. Tumor cells with constitutive expression of activated integrin $\alpha_v\beta_3$ had significantly greater proliferation in the mouse striatum than cells expressing a nonactivated form ($p < 0.03$). Imaging and immunohistochemistry studies showed that the integrin increased angiogenesis and prevented hypoxia in cancer cells implanted in the brain. Next steps could include evaluating the inhibition of integrin $\alpha_v\beta_3$ in animal models of cancer metastasis to the brain.</p> <p>CNTO 95, a human antibody against integrin α_v, from Medarex Inc. and Johnson & Johnson, is in Phase II testing for multiple cancers.</p> <p>SciBX 2(25); doi:10.1038/scibx.2009.1000 Published online June 25, 2009</p>	Patent and licensing status unavailable	<p>Lorger, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 8, 2009; doi:10.1073/pnas.0903035106</p> <p>Contact: Brunhilde Felding-Habermann, The Scripps Research Institute, La Jolla, Calif. e-mail: brunie@scripps.edu</p>